Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 1, 2012, Pages 11-22

  Lin, Liguo ^a   Zhong, Kaihua ^a   Sun, Zhongkai ^a   Wu, Guozhong ^a   Ding, Guodong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Etastasis; Igh; Ignal transduction; Obility group box 1 (HMGB1); Receptor for advanced glycation end products (RAGE); Roliferation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; KI 67 ANTIGEN; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR VOLUME; WESTERN BLOTTING; WOUND HEALING;

CARCINOMA, RENAL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER;

EID: 84863416913     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1067-0     Document Type: Article

References (50)

1. Arumugam T, Ramachandran V, Logsdon CD (2006) Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 98: 1806-1818 (Pubitemid 46017932)
2. Ather MH, Masood N, Siddiqui T (2010) Current management of advanced and metastatic renal cell carcinoma. Urol J 7: 1-9
3. Barlovic DP, Thomas MC, Jandeleit-Dahm K (2010) Cardiovascular disease: what's all the AGE/RAGE about? Cardiovasc Hematol Disord Drug Targets 10: 7-15
4. Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, Viani P, Sparatore B, Melloni E, Riboni L (2008) HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 87: 23-33
5. Baud V, Jacque E (2008) The alternative NF-kB activation pathway and cancer: friend or foe? Med Sci (Paris) 24: 1083-1088
6. Bianchi R, Kastrisianaki E, Giambanco I, Donato R (2011) S100B protein stimulates microglia migration via RAGE-dependent upregulation of chemokine expression and release. J Biol Chem 286: 7214-7226
7. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52: 2251-2263
8. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. Faseb J 17: 1295-1297
9. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7: 38
10. Cirillo P, Cali G, Golino P, Calabro P, Forte L, De Rosa S, Pacileo M, Ragni M, Scopacasa F, Nitsch L, Chiariello M (2004) Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109: 2911-2916 (Pubitemid 38780307)
11. Erdogan F, Demirel A, Polat O (2004) Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract 58: 333-336 (Pubitemid 38714436)
12. Evans A, Lennard TW, Davies BR (2004) High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol 88: 86-99 (Pubitemid 39536509)
13. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205: 275-285 (Pubitemid 351281593)
14. Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684 (Pubitemid 44657845)
15. Huang W, Liu Y, Li L, Zhang R, Liu W, Wu J, Mao E, Tang Y (2011) HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation. doi: 10.1007/s10753-011-9325-5
16. Jiao Y, Wang HC, Fan SJ (2007) Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28: 1957-1967 (Pubitemid 350198338)
17. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ (2010) The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 17: 666-676
18. Kim SW, Lim CM, Kim JB, Shin JH, Lee S, Lee M, Lee JK (2010) Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res 20: 159-169
19. Kojro E, Postina R (2009) Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J Alzheimers Dis 16: 865-878
20. Kostova N, Zlateva S, Ugrinova I, Pasheva E (2010) The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258
21. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170 (Pubitemid 34110897)
22. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448
23. Lockman K, Hinson JS, Medlin MD, Morris D, Taylor JM, Mack CP (2004) Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors. J Biol Chem 279: 42422-42430 (Pubitemid 39372124)
24. Logsdon CD, Fuentes MK, Huang EH, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7: 777-789
25. Luo Y, Ohmori H, Fujii K, Moriwaka Y, Sasahira T, Kurihara M, Tatsumoto N, Sasaki T, Yamashita Y, Kuniyasu H (2010) HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur J Cancer 46: 791-799
26. Ma H, SY Li, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13: 1751-1764
27. Maruyama I (2010) HMGB1. Nippon Rinsho 68(Suppl 7): 137-140
28. Miki S, Kasayama S, Miki Y, Nakamura Y, Yamamoto M, Sato B, Kishimoto T (1993) Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 196: 984-989 (Pubitemid 23337704)
29. Miller DC, Ruterbusch J, Colt JS, Davis FG, Linehan WM, Chow WH, Schwartz K (2010) Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based casecontrol study. J Urol 184: 2254-2258
30. Mohammed A, Shergill I, Little B (2009) Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn 9: 75-83
31. Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J, Wake N (2004) K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 64: 2759-2765 (Pubitemid 38500613)
32. Ohmori H, Luo Y, Kuniyasu H (2011) Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets 15: 183-193
33. Riehl A, Nemeth J, Angel P, Hess J (2009) The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal 7: 12
34. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA (2011) Cancer and leukemia group b pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol 29: 2282-2290
35. Riuzzi F, Sorci G, Donato R (2006) The amphoterin (HMGB1)/ receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 281: 8242-8253 (Pubitemid 43847445)
36. Riuzzi F, Sorci G, Donato R (2007) RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 171: 947-961 (Pubitemid 47440993)
37. Sakuraoka Y, Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Ohsawa T, Adachi M, Takino J, Takeuchi M, Kubota K (2010) MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 16: 5334-5341
38. Sandim V, Pereira DA, Ornellas AA, Alves G (2010) Renal cell carcinoma and proteomics. Urol Int 84: 373-377
39. Sangle GV, Zhao R, Mizuno TM, Shen GX (2010) Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Endocrinology 151: 4455-4466
40. Sasahira T, Akama Y, Fujii K, Kuniyasu H (2005) Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 411-415 (Pubitemid 40674848)
41. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, Kuniyasu H (2007) The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 450: 287-295 (Pubitemid 46376559)
42. Shang L, Ananthakrishnan R, Li Q, Quadri N, Abdillahi M, Zhu Z, Qu W, Rosario R, Toure F, Yan SF, Schmidt AM, Ramasamy R (2010) RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One 5: e10092
43. Sims GP, Rowe DC, Rietdijk ST, Herbst H, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388
44. Sviatoha V, Tani E, Kleina R, Sperga M, Skoog L (2010) Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. Melanoma Res 20: 118-125
45. Taguchi A, Blood DC, Del TG, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360 (Pubitemid 30337069)
46. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y (2009) Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 46: 572-580
47. Tolboom TC, Huizinga TW (2007) In vitro matrigel fibroblast invasion assay. Methods Mol Med 135: 413-421
48. Villarreal A, Aviles RR, Angelo MF, Reines AG, Ramos AJ (2011) S100B alters neuronal survival and dendrite extension via RAGEmediated NF-kappaB signaling. J Neurochem 117: 321-332
49. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, Joos S, Zornig M (2006) Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242 (Pubitemid 43117284)
50. Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94: 2511-2516 (Pubitemid 34457134)